Novo Nordisk, the Danish global healthcare company, received the all clear a few month ago from the US, EU and Canada to launch and sell a new treatment for Weight Management, Saxenda. The company announced the launch of Saxenda in the US, who present the treatment as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity or who are overweight.
Obesity is a disease that requires chronic management. It is associated with serious comorbidities including type 2 diabetes, heart disease, certain types of cancer and a decreased life expectancy. Obesity is a complex and multifactorial disease that is influenced by genetic, physiological, environmental and psychological factors. The global increase of the prevalence of obesity is a public health issue that has severe cost implications to healthcare systems, not only in the US , but worldwide. In 2011-2012 in the US, approximately 35% of adults, or nearly 80 million adults, lived with this desease.
Saxenda is a once-daily-intake glucagon-like peptide-1 (GLP-1) analogue with 97% similarity to naturally occurring human GLP-1,13 a hormone that is released in response to food consumption. Like human GLP-1, Saxenda regulates appetite and lowers body weight by reducing food intake. As with other GLP-1 receptor agonists, liraglutide stimulates insulin secretion and reduces glucagon secretion in a glucose-dependent manner. Trial data showed that Saxenda, in combination with a reduced-calorie diet and increased physical activity, resulted in greater weight loss than reduced calorie diets and physical activity alone for people who have obesity (BMI >=30 kg/m2) or who are overweight (BMI >=27 kg/m2) with weight-related comorbidities.
Executive Vice President Jakob Riis, Marketing, Medical Affairs & Stakeholder Engagement of Novo Nordisk explained: “The launch of Saxenda is an important milestone in Novo Nordisk’s long-term commitment to obesity treatment and we look forward to launching Saxenda in other countries later in 2015.”
Let's Continue The Conversation
Feel free to send us comments about this article to firstname.lastname@example.org and/or comment on that article on social media.